XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 31.80

-0.1%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (7754)	11/18/1998 2:12:00 AM
From: aknahow	Read Replies (1) of 17367

What is Angiogenesis? med.chungbuk.ac.kr This is from non XOMA source. It might have been posted years ago. I am not sure it has any real value in terms of stock price performance but it is very comprehensive. Selected sample: "In the coming years, the two areas where growth will be greatest in the cancer market are in angiogenesis treatments and cytotoxic agents (agents that kill cancer cells) that work along new pathways. Angiotech is developing promising technologies in each of these areas. (Sources - American Association of Cancer Research, "Recent Progress and Future Opportunities in Cancer Research", 1995; Find/SVP, Inc., "The Market for Cancer Therapeutics and Diagnostics - A Market Intelligence Report", 1992) " Newer site: medscape.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next